{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-030968","form_type":"8-K","ticker":"OMER","cik":"0001285819","company_name":"OMEROS CORP","filed_at":"2025-10-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.029283+00:00","generated_at":"2026-05-17T03:41:20.007845+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Omeros sells global rights to zaltenibart to Novo Nordisk for up to $2.1B","bullets":["Upfront $240M cash plus near-term milestones total $340M; up to $2.1B including development & sales milestones plus tiered royalties.","Novo Nordisk gains exclusive global rights to develop and commercialize MASP-3 inhibitor zaltenibart in all indications.","Omeros will use part of upfront to repay $67.1M term loan; remaining funds support narsoplimab approval and preclinical pipeline.","Transaction expected to close Q4 2025, subject to HSR clearance and customary conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-030968","json":"https://secwatch.observer/filing/0001437749-25-030968.json","markdown":"https://secwatch.observer/filing/0001437749-25-030968.md","text":"https://secwatch.observer/filing/0001437749-25-030968.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285819/000143774925030968/0001437749-25-030968-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285819/000143774925030968/omer20251014_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:41:20.007845+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}